Literature DB >> 2524504

Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

D E Hughes1, B R MacDonald, R G Russell, M Gowen.   

Abstract

Bisphosphonates inhibit bone resorption in vivo and in vitro by unknown mechanisms. The effect of bisphosphonates on the formation of osteoclasts from their mononuclear hematopoietic precursors was investigated using human long-term marrow cultures in which multinucleated cells form that express most of the known features of the osteoclast phenotype (e.g., bone resorption, tartrate-resistant acid phosphatase, calcitonin responsiveness, and reactivity with specific MAbs). The five bisphosphonates that were tested strongly inhibited 1,25-dihydroxyvitamin D3-stimulated formation of these cells with the same relative potencies as they inhibit bone resorption in vivo. Two representative compounds (3-amino-1-hydroxypropylidene-1,1-bisphosphonate and dichloromethylene bisphosphonate) failed to inhibit the proliferation of precursors of the osteoclast-like cells. However, these compounds decreased the proportion of mononuclear and multinucleated cells expressing an osteoclast antigen, thus suggesting a degree of specificity for cells of the osteoclast lineage. We conclude that bisphosphonates are potent inhibitors of osteoclast-like cell formation in long-term human marrow cultures, and that this may be related to their ability to inhibit bone resorption in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524504      PMCID: PMC303914          DOI: 10.1172/JCI114100

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages.

Authors:  P H Stevenson; J R Stevenson
Journal:  Calcif Tissue Int       Date:  1986-04       Impact factor: 4.333

2.  Kinetic and cytochemical identification of osteoclast precursors and their differentiation into multinucleated osteoclasts.

Authors:  R Baron; L Neff; P Tran Van; J R Nefussi; A Vignery
Journal:  Am J Pathol       Date:  1986-02       Impact factor: 4.307

3.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

4.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

5.  Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens.

Authors:  M A Horton; D Lewis; K McNulty; J A Pringle; T J Chambers
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

6.  Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

Authors:  S H Ralston; M D Gardner; F J Dryburgh; A S Jenkins; R A Cowan; I T Boyle
Journal:  Lancet       Date:  1985-10-26       Impact factor: 79.321

7.  Effect of bisphosphonates on prostaglandin synthesis by rat bone cells and mouse calvaria in culture.

Authors:  K Ohya; S Yamada; R Felix; H Fleisch
Journal:  Clin Sci (Lond)       Date:  1985-10       Impact factor: 6.124

8.  Recombinant human transforming growth factor-alpha stimulates the formation of osteoclast-like cells in long-term human marrow cultures.

Authors:  N Takahashi; B R MacDonald; J Hon; M E Winkler; R Derynck; G R Mundy; G D Roodman
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

9.  Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.

Authors:  D L Douglas; T Duckworth; R G Russell; J A Kanis; C J Preston; F E Preston; M A Prenton; J S Woodhead
Journal:  Lancet       Date:  1980-05-17       Impact factor: 79.321

10.  Treatment of malignant hypercalcaemia with clodronate.

Authors:  R C Percival; A D Paterson; A J Yates; D J Beard; D L Douglas; F E Neal; R G Russell; J A Kanis
Journal:  Br J Cancer       Date:  1985-05       Impact factor: 7.640

View more
  83 in total

Review 1.  Endocrinology.

Authors:  M A Baxter; M C Sheppard
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

2.  Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures.

Authors:  Yuwei Wang; Alexandra Panasiuk; David W Grainger
Journal:  Mol Pharm       Date:  2011-01-21       Impact factor: 4.939

3.  Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation.

Authors:  Lindsay M Coe; Srinivasan Arjun Tekalur; Yutian Shu; Melissa J Baumann; Laura R McCabe
Journal:  J Cell Physiol       Date:  2015-08       Impact factor: 6.384

4.  Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin.

Authors:  Z Zimolo; G Wesolowski; G A Rodan
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

Review 5.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

6.  Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study.

Authors:  Hyung Keun Kim; Ji Hyun Kim; Azlina Amir Abbas; Taek Rim Yoon
Journal:  Clin Orthop Relat Res       Date:  2008-07-30       Impact factor: 4.176

7.  Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo.

Authors:  Y Endo; M Nakamura; T Kikuchi; H Shinoda; Y Takeda; Y Nitta; K Kumagai
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

Review 8.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

9.  Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.

Authors:  M Sahni; H L Guenther; H Fleisch; P Collin; T J Martin
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

10.  Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.

Authors:  A M Flanagan; T J Chambers
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.